Company to continue integrating AI across operations to improve efficiency and profitability
111 Inc plans to expand pharmaceutical product portfolio to consolidate market position
Company expects asset-light transition and cost management to support margin expansion
Overview
China healthcare platform's Q2 revenue fell 28% yr/yr amid asset-light business transition
Company reported wider net and adjusted net losses due to severance costs and AI investment
Promotional products revenue more than doubled, offsetting some of the overall revenue decline
Key details
Metric
Actual
Q2 Revenue
RMB 2.30 bln
Q2 Adjusted Net Loss
RMB 28.90 mln
Q2 Net Loss
RMB 31.70 mln
Q2 Adjusted Income From Operations
-RMB 20.50 mln
Q2 Income From Operations
-RMB 23.20 mln
Result Drivers
Asset-light transition - Co said revenue decline was mainly due to strategic shift to asset-light model and divestment of underperforming subsidiaries
- Co said promotional products revenue and gross profit rose sharply due to expanded partnerships and increased sales volumes, especially for Levofloxacin Tablets
Cost management - Co said fulfillment and operating expenses declined, aided by AI-driven workforce streamlining and selective exits from fulfillment centers
YI•
